Q-omics provides the consensus-scored LMAN2L profile across patient tissues and cancer cell-line models. LMAN2L expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LMAN2L is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, LMAN2L RNA expression shows 19,526 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where LMAN2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMAN2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMAN2L survival associations across molecular data types. LMAN2L RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMAN2L RNA expression–survival associations across cancer types. High LMAN2L expression shows unfavorable associations in ACC, LIHC, BLCA, LGG and KIRP, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LMAN2L RNA expression.
This table summarizes LMAN2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LMAN2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMAN2L shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, KIRC, KIRP and LIHC. The HNSC box plot shows higher LMAN2L RNA expression in tumor versus normal tissue (log2 FC = +0.978, t-test p < 0.001).
This table shows molecular features associated with LMAN2L in patient tissues and cancer cell lines. In patient samples, LMAN2L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LMAN2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
